Skip Navigation


JAC Advance Access originally published online on June 12, 2008
Journal of Antimicrobial Chemotherapy 2008 62(3):637-639; doi:10.1093/jac/dkn236
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
62/3/637    most recent
dkn236v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tzelepi, E.
Right arrow Articles by Flemetakis, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tzelepi, E.
Right arrow Articles by Flemetakis, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Research letters

Cluster of multidrug-resistant Neisseria gonorrhoeae with reduced susceptibility to the newer cephalosporins in Northern Greece

Eva Tzelepi1,*, Maria Daniilidou2, Vivi Miriagou1, Eirini Siatravani1, Efthimia Pavlidou2 and Alexandros Flemetakis3

1 Laboratory of Bacteriology of the Hellenic Pasteur Institute, National Reference Centre for Neisseria gonorrhoeae, 127 Vas. Sofias Ave., 11521 Athens, Greece 2 Laboratory of Microbiology, Venereal and Skin Diseases Hospital of Thessaloniki, Thessaloniki, Greece 3 Microbiology Laboratory of the ‘Andreas Sygros’ Hospital for Skin and Venereal Diseases, Athens, Greece

* Corresponding author. Tel: +30-210-64-78-810; Fax: +30-210-64-40-171; E-mail: tzelepi@pasteur.gr

Keywords: gonorrhoea , therapy , STD

The first 10% of the full text of this article appears below.

Sir,

Therapeutic options for gonococcal infection are nowadays limited due to the spread of gonococci resistant to a wide variety of antimicrobials. The dramatic increments in the rates of quinolone-resistant gonococci and the current shortage of spectinomycin leave the newer cephalosporins as the last safe choice among the drugs that are currently recommended as first-line treatment. Therefore, increasing reports of reduced in vitro activities of expanded-spectrum cephalosporins against Neisseria gonorrhoeae are of serious concern.1–5

The aim of this report from the Greek National . . . [Full Text of this Article]


   Funding
 

   Transparency declarations
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?